SiontisKC, . Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. Circulation 2018. http://doi.org/10.1161/CIRCULATIONAHA.118.035418].10.1161/CIRCULATIONAHA.118.035418)| false
In dialysis patients with atrial fibrillation, the factor Xa inhibitor apixaban reduced the risk of major bleeding compared to warfarin in a nationwide sample, reports a study in Circulation.
Standard-dose apixaban is also associated with lower risks of thromboembolism and death compared to warfarin.
The introduction of direct oral anticoagulants has changed the approach to management of stroke risk in patients with atrial fibrillation. But the pivotal trials of these agents excluded atrial fibrillation patients with kidney failure. Some studies have reported adverse outcomes with dabigatran and rivaroxaban in this patient population. Standard-dose apixaban is approved for use